Geron (1GERN) Stock Overview
A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
1GERN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Geron Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.27 |
| 52 Week High | US$1.58 |
| 52 Week Low | US$0.94 |
| Beta | 0.59 |
| 1 Month Change | 0.12% |
| 3 Month Change | 18.97% |
| 1 Year Change | 6.08% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1GERN | IT Biotechs | IT Market | |
|---|---|---|---|
| 7D | -2.9% | -2.5% | -0.1% |
| 1Y | 6.1% | 19.7% | 21.8% |
Return vs Industry: 1GERN underperformed the Italian Biotechs industry which returned 19.7% over the past year.
Return vs Market: 1GERN underperformed the Italian Market which returned 21.8% over the past year.
Price Volatility
| 1GERN volatility | |
|---|---|
| 1GERN Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in IT Market | 8.1% |
| 10% least volatile stocks in IT Market | 2.8% |
Stable Share Price: 1GERN's share price has been volatile over the past 3 months compared to the Italian market.
Volatility Over Time: 1GERN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Italian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 258 | Harout Semerjian | www.geron.com |
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation Fundamentals Summary
| 1GERN fundamental statistics | |
|---|---|
| Market cap | €816.46m |
| Earnings (TTM) | -€58.45m |
| Revenue (TTM) | €176.84m |
Is 1GERN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1GERN income statement (TTM) | |
|---|---|
| Revenue | US$204.56m |
| Cost of Revenue | US$84.89m |
| Gross Profit | US$119.67m |
| Other Expenses | US$187.29m |
| Earnings | -US$67.61m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | 58.50% |
| Net Profit Margin | -33.05% |
| Debt/Equity Ratio | 55.0% |
How did 1GERN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/16 05:05 |
| End of Day Share Price | 2026/08/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Geron Corporation is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Buchanan | Brean Capital Historical (Janney Montgomery) |
| Thomas Shrader | BTIG |
| Charles Duncan | Citizens JMP Securities, LLC |